Alnylam Pharmaceuticals (LTS:0HD2) Shares Buyback Ratio %: -2.10 (As of Sep. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0HD2 Alnylam Pharmaceuticals Inc LTS:0HD2
65 GF Score
Price $239.90
GF Value $533.20
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Alnylam Pharmaceuticals Shares Buyback Ratio %?

Alnylam Pharmaceuticals LTS:0HD2 -0.25% 65 Shares Buyback Ratio % is -2.10 as of Sep. 17, 2026. GuruFocus rates LTS:0HD2 with a GF Score™ of 65/100 and a GF Value™ of $533.20 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

GuruFocus calculates shares buyback ratio using previous shares outstanding minus the current shares outstanding, and then divides by previous shares outstanding. Alnylam Pharmaceuticals's current shares buyback ratio was -2.10%.

Alnylam Pharmaceuticals Shares Buyback Ratio % Related Terms

Alnylam Pharmaceuticals Shares Buyback Ratio % Historical Data

* Premium members only.

The historical data trend for Alnylam Pharmaceuticals's Shares Buyback Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alnylam Pharmaceuticals Shares Buyback Ratio % Chart

Alnylam Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Buyback Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.23 -3.11 -1.51 -2.78 -2.38

Alnylam Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shares Buyback Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.51 -0.62 -0.44 -0.81 -0.22
LTS:0HD2
65GF Score
Alnylam Pharmaceuticals Inc LTS:0HD2
Shares Buyback Ratio % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alnylam Pharmaceuticals Shares Buyback Ratio % Calculation

Alnylam Pharmaceuticals's Shares Buyback Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Dec. 2024 ) - Shares Outstanding (EOP) (A: Dec. 2025 )) / Shares Outstanding (EOP) (A: Dec. 2024 )
=(129.294 - 132.376) / 129.294
=-2.38%

Alnylam Pharmaceuticals's Shares Buyback Ratio for the quarter that ended in Jun. 2026 is calculated as

Shares Buyback Ratio=(Shares Outstanding (EOP) (A: Mar. 2026 ) - Shares Outstanding (EOP) (A: Jun. 2026 )) / Shares Outstanding (EOP) (A: Mar. 2026 )
=(133.444 - 133.734) / 133.444
=-0.22%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Shares Buyback Ratio % →
What does a Shares Buyback Ratio % of -2.10 mean?
Alnylam Pharmaceuticals (LTS:0HD2) has a Shares Buyback Ratio % of -2.10 as of Sep. 17, 2026. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Alnylam Pharmaceuticals and its competitors.
Is Alnylam Pharmaceuticals' Shares Buyback Ratio % too high?
Alnylam Pharmaceuticals' current Shares Buyback Ratio % is -2.10. Overall, Alnylam Pharmaceuticals has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Shares Buyback Ratio % compare to RPRX and INSM?
Alnylam Pharmaceuticals' Shares Buyback Ratio % of -2.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Buyback Ratio % for a Biotechnology company?
A good Shares Buyback Ratio % depends on the Biotechnology industry context. However, Shares Buyback Ratio % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Buyback Ratio % mean?
A high Shares Buyback Ratio % can signal that a stock is expensive relative to its fundamentals. Share buyback ratio is the percent change of a company's shares outstanding from two periods. View historical data on Alnylam Pharmaceuticals and its competitors. Alnylam Pharmaceuticals's current Shares Buyback Ratio % is -2.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $533.20, compared to a current price of $239.90 — trading 55% below its estimated fair value. The current Shares Buyback Ratio % is -2.10. Alnylam Pharmaceuticals' overall GF Score™ is 65/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Buyback Ratio % calculated?
Shares Buyback Ratio % is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Shares Buyback Ratio % is -2.10 as of Sep. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?

Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued. The current stock price of $239.90 is trading 55% below its estimated GF Value™ of $533.20. GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for LTS:0HD2:

  • Shares Buyback Ratio %: -2.10
  • GF Value™: $533.20 vs. price of $239.90 (55% below fair value)
  • GF Score™: 65/100 with 1 warning sign

No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alnylam Pharmaceuticals Business Description

Address 675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
65GF Score

Get the complete analysis for LTS:0HD2

Shares Buyback Ratio % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$239.90
Price
$533.20
GF Value